These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Kralovics R; Teo SS; Li S; Theocharides A; Buser AS; Tichelli A; Skoda RC Blood; 2006 Aug; 108(4):1377-80. PubMed ID: 16675710 [TBL] [Abstract][Full Text] [Related]
9. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100 [TBL] [Abstract][Full Text] [Related]
10. Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Perner F; Perner C; Ernst T; Heidel FH Cells; 2019 Aug; 8(8):. PubMed ID: 31398915 [TBL] [Abstract][Full Text] [Related]
11. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. Staerk J; Constantinescu SN JAKSTAT; 2012 Jul; 1(3):184-90. PubMed ID: 24058768 [TBL] [Abstract][Full Text] [Related]
13. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Bellucci S; Michiels JJ Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614 [TBL] [Abstract][Full Text] [Related]
14. Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 Wang W; Liu W; Fidler T; Wang Y; Tang Y; Woods B; Welch C; Cai B; Silvestre-Roig C; Ai D; Yang YG; Hidalgo A; Soehnlein O; Tabas I; Levine RL; Tall AR; Wang N Circ Res; 2018 Nov; 123(11):e35-e47. PubMed ID: 30571460 [TBL] [Abstract][Full Text] [Related]
15. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895 [TBL] [Abstract][Full Text] [Related]
16. [Somatic mutation of the V617F JAK2 gene in patients of the cardiovascular diseases]. Olkhovskiy IA; Gorbenko AS; Stolyar MA; Grischenko DA; Tkachenko OA; Martsinkevich TL Ter Arkh; 2019 Jul; 91(7):25-28. PubMed ID: 32598732 [TBL] [Abstract][Full Text] [Related]
17. Polycythemia vera is not initiated by JAK2V617F mutation. Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871 [TBL] [Abstract][Full Text] [Related]
18. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940 [TBL] [Abstract][Full Text] [Related]
19. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies. Kreft A; Kindler T; Springer E; Kirkpatrick CJ Virchows Arch; 2011 Nov; 459(5):521-7. PubMed ID: 22006129 [TBL] [Abstract][Full Text] [Related]
20. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]